Abstract:Arrhythmia and cardiac hypertrophy are two very common cardiovascular diseases that can lead to heart failure and even sudden death, thus presenting a serious threat to human life and health. According to global statistics, nearly one million people per year die from arrhythmia, cardiac hypertrophy and other associated cardiovascular diseases. Hence, there is an urgent need to find new treatment targets and to develop new intervention measures. Recently, mitochondrial dysfunction has been examined in relation to heart disease with a view to lowering the incidence of arrhythmia and cardiac hypertrophy. The heart is the body's largest energy consuming organ, turning over about 20 kg of adenosine triphosphate (ATP) per day in the mitochondria. Mitochondrial oxidative phosphorylation (OXPHOS) produces up to 90% of the ATP needed by cardiac muscle cells for contraction and relaxation. Dysfunction of heart mitochondria can therefore induce arrhythmia, cardiac hypertrophy and other cardiovascular diseases. Mitochondrial DNA (mtDNA) mutations cause disorders in OXPHOS and defects in the synthesis of muscle contraction proteins. These lead to insufficient production of secondary ATP, increased metabolic requirements for ATP by the myocardium, and the accumulation of reactive oxygen species (ROS). The resulting damage to myocardial cells eventually induces arrhythmia and cardiac hypertrophy. Mitochondrial damage decreases the efficiency of energy production, which further increases the production of ROS. The accumulation of ROS causes mitochondrial damage and eventually leads to a vicious cycle of mitochondrial damage and low efficiency of mitochondrial energy production. In this review, the mechanism underlying the development of arrhythmia and cardiac hypertrophy is described in relation to mitochondrial energy supply, oxidative stress, mtDNA mutation and Mitochondrial dynamics. Targeted therapy for arrhythmia and cardiac hypertrophy induced by mitochondrial dysfunction is also discussed in terms of its potential clinical value. These strategies should improve our understanding of mitochondrial biology and the pathogenesis of arrhythmia and cardiac hypertrophy. They may also identify novel strategies for targeting mitochondria in the treatment of these diseases.

Mitochondrial Dysfunction Increases Arrhythmic Triggers and Substrates; Potential Anti-arrhythmic Pharmacological Targets

Mitochondrial Dysfunction: A Roadmap for Understanding and Tackling Cardiovascular Aging.

Mitochondrial Dysfunction in Arrhythmia and Cardiac Hypertrophy

Regulatory Mechanisms of Mitochondrial Function and Cardiac Aging

Mitochondrial proton leak in cardiac aging

Mitochondrial Dysfunction in Atrial Fibrillation: The Need for a Strong Pharmacological Approach

Mechanistic and Therapeutic Perspectives for Cardiac Arrhythmias: Beyond Ion Channels

Relevance of mitochondrial oxidative stress to arrhythmias: Innovative concepts to target treatments

Anti‐malarial drugs: mechanisms underlying their proarrhythmic effects

Mitochondrial Regulation Of Cardiac Aging

The dynamic interplay between cardiac mitochondrial health and myocardial structural remodeling in metabolic heart disease, aging, and heart failure

Mitophagy Receptors and Mediators: Therapeutic Targets in the Management of Cardiovascular Ageing.

Mechanisms Underlying Na+/K+-ATPase Inhibition-Induced Mitochondrial Dysfunction and Abnormal Action Potentials

Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer's Disease: Recent Advances and Therapeutic Implications

Targeting Mitochondrial Oxidative Stress as a Strategy to Treat Aging and Age-Related Diseases

Skeletal muscle bioenergetics in aging and heart failure

Mitochondrial Dysfunction Underlies Cardiomyocyte Remodeling in Experimental and Clinical Atrial Fibrillation

Advances in Cardiotoxicity Induced by Altered Mitochondrial Dynamics and Mitophagy

Mitophagy: At the heart of mitochondrial quality control in cardiac aging and frailty

Mitochondrial Function in Ageing: Coordination with Signalling and Transcriptional Pathways.

Mitochondrial Dysfunction-Associated Arrhythmogenic Substrates in Diabetes Mellitus